Abstract
High glucose uptake is a characteristic of most metastatic tumors and activation of Ras signaling in immortalized cells increases glycolytic flux into lactate, de novo nucleic acid synthesis and the tricarboxylic acid cycle, and increases NADH shuttling, oxygen consumption and uncoupling of ATP synthase from the proton gradient. Fructose-2,6- bisphosphate, C-Myc, HIF1α and AKT each have been found to be key regulators of glycolysis and to be controlled by Ras signaling, and there is abundant evidence for cross-talk between these regulators. The reprogramming of glycolytic and mitochondrial metabolism by Ras enables an integrated activation of energetic and anabolic pathways via the redox state of NADH that is required for the survival and growth of neoplastic cells in poorly vascularized tumors. Several small molecule antagonists specific for essential metabolic enzymes have been found to be selectively toxic to Ras-transformed cells as opposed to wild-type cells, indicating that this metabolic reprogramming and addiction may have utility for the development of anti-neoplastic agents.
Keywords: C-Myc, glycolysis, HIF1α, mitochondria, metabolism, phosphofructokinase, Ras
Current Pharmaceutical Biotechnology
Title:Regulation of Glycolytic and Mitochondrial Metabolism by Ras
Volume: 14 Issue: 3
Author(s): J. Chesney and S. Telang
Affiliation:
Keywords: C-Myc, glycolysis, HIF1α, mitochondria, metabolism, phosphofructokinase, Ras
Abstract: High glucose uptake is a characteristic of most metastatic tumors and activation of Ras signaling in immortalized cells increases glycolytic flux into lactate, de novo nucleic acid synthesis and the tricarboxylic acid cycle, and increases NADH shuttling, oxygen consumption and uncoupling of ATP synthase from the proton gradient. Fructose-2,6- bisphosphate, C-Myc, HIF1α and AKT each have been found to be key regulators of glycolysis and to be controlled by Ras signaling, and there is abundant evidence for cross-talk between these regulators. The reprogramming of glycolytic and mitochondrial metabolism by Ras enables an integrated activation of energetic and anabolic pathways via the redox state of NADH that is required for the survival and growth of neoplastic cells in poorly vascularized tumors. Several small molecule antagonists specific for essential metabolic enzymes have been found to be selectively toxic to Ras-transformed cells as opposed to wild-type cells, indicating that this metabolic reprogramming and addiction may have utility for the development of anti-neoplastic agents.
Export Options
About this article
Cite this article as:
Chesney J. and Telang S., Regulation of Glycolytic and Mitochondrial Metabolism by Ras, Current Pharmaceutical Biotechnology 2013; 14(3) . https://dx.doi.org/10.2174/1389201011314030002
DOI https://dx.doi.org/10.2174/1389201011314030002 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Minifish Shows High Genetic Variation in mtDNA Size
Current Molecular Medicine Lipid Nanoparticles as a Skin Wound Healing Drug Delivery System: Discoveries and Advances
Current Pharmaceutical Design An Update on Clinical Drug Interactions with the Herbal Antidepressant St. Johns wort
Current Drug Metabolism Cancer Chemoprevention Drug Targets
Current Drug Targets Green Synthesis of Silver Nanocomposites of Nigella sativa Seeds Extract for Hepatocellular Carcinoma
Current Nanomaterials Novel Therapies Against Aggressive and Recurrent Epithelial Cancers by Molecular Targeting Tumor- and Metastasis-Initiating Cells and Their Progenies
Anti-Cancer Agents in Medicinal Chemistry Glucose-6-phosphate Dehydrogenase: a Biomarker and Potential Therapeutic Target for Cancer
Anti-Cancer Agents in Medicinal Chemistry Peptides as Signaling Inhibitors for Mammalian MAP Kinase Cascades
Current Pharmaceutical Design Potential Use of Dietary Natural Products, Especially Polyphenols, for Improving Type-1 Allergic Symptoms
Current Pharmaceutical Design Chemical Inhibition of Matrix Metalloproteinases for Periodontal Treatment
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Toxicity of Magnetic Resonance Imaging Agents: Small Molecule and Nanoparticle
Current Topics in Medicinal Chemistry Integrated UPLC-MS/MS and UHPLC-Q-orbitrap HRMS Analysis to Reveal Pharmacokinetics and Metabolism of Five Terpenoids from <i>Alpiniae oxyphyllae</i> Fructus in Rats
Current Drug Metabolism Design and Structure of Peptide and Peptidomimetic Antagonists of Protein- Protein Interaction
Current Protein & Peptide Science Preface
Current Pharmaceutical Design Ganglioside GD3 as a Raft Component in Cell Death Regulation
Anti-Cancer Agents in Medicinal Chemistry Insight View on Synthetic Strategies and Biological Applications of Pyrimidobenzothiazoles
Mini-Reviews in Organic Chemistry The Significance of Ubiquitin Proteasome Pathway in Cancer Development
Recent Patents on Anti-Cancer Drug Discovery Overview of the Metallometabolomic Methodology for Metal-Based Drug Metabolism
Current Drug Metabolism Cancer-associated Autoantibodies as Biomarkers for Early Detection and Prognosis is Cancer: An Update
Current Cancer Therapy Reviews Transcriptional and Post-Transcriptional Regulations of Junction Proteins in Mammalian estes – Implications on Male Contraceptive Development
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)